MA31358B1 - Méthodes de traitement du cancer à l'aide d'inhibiteurs de pi3k alpha à base de pyridopyrimidinone - Google Patents
Méthodes de traitement du cancer à l'aide d'inhibiteurs de pi3k alpha à base de pyridopyrimidinoneInfo
- Publication number
- MA31358B1 MA31358B1 MA32318A MA32318A MA31358B1 MA 31358 B1 MA31358 B1 MA 31358B1 MA 32318 A MA32318 A MA 32318A MA 32318 A MA32318 A MA 32318A MA 31358 B1 MA31358 B1 MA 31358B1
- Authority
- MA
- Morocco
- Prior art keywords
- pyridoperimidone
- ways
- treat cancer
- pi3k inhibitors
- inhibitors based
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000012828 PI3K inhibitor Substances 0.000 title 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title 1
- 238000011394 anticancer treatment Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
La présente invention concerne des méthodes de traitement du cancer, consistant à administrer un composé représenté par la formule générale i, éventuellement sous forme de sel pharmaceutiquement acceptable, de solvate et/ou d'hydrate, conjointement avec d'autres traitements anticancéreux.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92289907P | 2007-04-10 | 2007-04-10 | |
PCT/US2008/004573 WO2008124161A1 (fr) | 2007-04-10 | 2008-04-09 | Méthodes de traitement du cancer à l'aide d'inhibiteurs de pi3k alpha à base de pyridopyrimidinone |
Publications (1)
Publication Number | Publication Date |
---|---|
MA31358B1 true MA31358B1 (fr) | 2010-05-03 |
Family
ID=39627802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA32318A MA31358B1 (fr) | 2007-04-10 | 2009-11-02 | Méthodes de traitement du cancer à l'aide d'inhibiteurs de pi3k alpha à base de pyridopyrimidinone |
Country Status (32)
Country | Link |
---|---|
US (1) | US8513266B2 (fr) |
EP (1) | EP2139484B9 (fr) |
JP (3) | JP2010523670A (fr) |
KR (1) | KR101626435B1 (fr) |
CN (2) | CN102727498B (fr) |
AU (1) | AU2008236562B2 (fr) |
BR (1) | BRPI0810206A2 (fr) |
CA (1) | CA2683641C (fr) |
CO (1) | CO6251254A2 (fr) |
CR (1) | CR11100A (fr) |
DK (1) | DK2139484T3 (fr) |
DO (1) | DOP2009000243A (fr) |
EA (1) | EA020022B1 (fr) |
EC (1) | ECSP099724A (fr) |
ES (1) | ES2430614T3 (fr) |
HK (1) | HK1139863A1 (fr) |
HN (1) | HN2009003002A (fr) |
HR (1) | HRP20130688T1 (fr) |
IL (1) | IL201284A (fr) |
MA (1) | MA31358B1 (fr) |
ME (1) | ME00936B (fr) |
MX (1) | MX2009010930A (fr) |
MY (1) | MY150697A (fr) |
NZ (1) | NZ580110A (fr) |
PL (1) | PL2139484T3 (fr) |
PT (1) | PT2139484E (fr) |
RS (1) | RS52939B (fr) |
SI (1) | SI2139484T1 (fr) |
TN (1) | TN2009000400A1 (fr) |
UA (1) | UA100979C2 (fr) |
WO (1) | WO2008124161A1 (fr) |
ZA (1) | ZA200906764B (fr) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200726767A (en) * | 2005-07-04 | 2007-07-16 | Astrazeneca Ab | Chemical compounds 2 |
JP5270353B2 (ja) * | 2005-10-07 | 2013-08-21 | エクセリクシス, インク. | ホスファチジルイノシトール3−キナーゼインヒビターとその使用方法 |
BRPI0617159B8 (pt) * | 2005-10-07 | 2021-05-25 | Exelixis Inc | compostos de piridopirimidinone inibidores de pi3ka, composições que os contem e processo para preparo |
AU2007284562B2 (en) | 2006-08-16 | 2013-05-02 | Exelixis, Inc. | Using PI3K and MEK modulators in treatments of cancer |
US8188113B2 (en) * | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
SA08280783B1 (ar) * | 2007-01-11 | 2011-04-24 | استرازينيكا ايه بي | مشتقات بيريدوبيريميدين كمثبطات pde4 |
UA100979C2 (ru) | 2007-04-10 | 2013-02-25 | Экселиксис, Инк. | Применение пиридопиримидиноновых ингибиторов pi3k альфа для лечения рака |
WO2008127594A2 (fr) * | 2007-04-11 | 2008-10-23 | Exelixis, Inc. | Procédés de traitement impliquant l'inhibition de pi3k-alpha au moyen d'inhibiteurs de type quinaxoline |
TW201020245A (en) | 2008-08-20 | 2010-06-01 | Schering Corp | Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
TW201020238A (en) * | 2008-08-20 | 2010-06-01 | Schering Corp | Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
TWI409265B (zh) | 2008-08-20 | 2013-09-21 | Merck Sharp & Dohme | 經取代之吡啶及嘧啶衍生物及彼等於治療病毒感染之用途 |
AR072938A1 (es) | 2008-08-20 | 2010-09-29 | Southern Res Inst | Derivados de piridina y pirimidina azosustituidos y su uso en el tratamiento de infecciones virales |
TW201139436A (en) | 2010-02-09 | 2011-11-16 | Exelixis Inc | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors |
WO2012027536A1 (fr) * | 2010-08-26 | 2012-03-01 | Bristol-Myers Squibb Company | Combinaison d'anticorps anti-ctla4 avec des inhibiteurs de braf pour le traitement synergique de maladies prolifératives |
WO2012037204A1 (fr) | 2010-09-14 | 2012-03-22 | Exelixis, Inc. | Inhibiteurs de pi3k-δ et leurs procédés d'utilisation et fabrication |
WO2012065019A2 (fr) | 2010-11-12 | 2012-05-18 | Exelixis, Inc. | Inhibiteurs pyridopyrimidinone de p13k alpha |
WO2012158960A2 (fr) * | 2011-05-17 | 2012-11-22 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Ligands du récepteur à la mélanocortine de type 1 et leurs procédés d'utilisation |
TW201306842A (zh) * | 2011-06-15 | 2013-02-16 | Exelixis Inc | 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法 |
EP2736325B1 (fr) * | 2011-07-28 | 2018-10-10 | F.Hoffmann-La Roche Ag | Modèle de cancer du sein d'animal non humain knock-in pik3ca h1047r |
WO2013056067A1 (fr) * | 2011-10-13 | 2013-04-18 | Exelixis, Inc. | Composés pour une utilisation dans le traitement de carcinome des cellules basales |
CN107375289A (zh) | 2011-11-01 | 2017-11-24 | 埃克塞利希斯股份有限公司 | 用于治疗淋巴组织增生性恶性肿瘤的作为磷脂酰肌醇3‑激酶抑制剂的化合物 |
WO2013071264A1 (fr) * | 2011-11-11 | 2013-05-16 | Intellikine, Llc | Combinaison d'inhibiteurs de kinase et ses utilisations |
WO2013101964A1 (fr) * | 2011-12-27 | 2013-07-04 | Kadmon Corporation, Llc | Procédés de traitement d'un cancer du sein ne répondant pas au trastuzumab |
US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
AU2013280644B2 (en) | 2012-06-26 | 2018-08-02 | Jeffrey A. BACHA | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
US8980259B2 (en) * | 2012-07-20 | 2015-03-17 | Novartis Ag | Combination therapy |
LT2882440T (lt) | 2012-08-07 | 2019-04-25 | Novartis Ag | Farmaciniai deriniai, apimantys b-raf slopiklį, egfr slopiklį ir nebūtinai pi3k-alfa slopiklį |
JP2016519684A (ja) | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | 準最適に投与された薬物療法の有効性を改善するための及び/又は副作用を低減するための方法および組成物 |
US9950194B2 (en) | 2014-09-09 | 2018-04-24 | Mevion Medical Systems, Inc. | Patient positioning system |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
KR20240014585A (ko) | 2016-03-04 | 2024-02-01 | 다이호야쿠힌고교 가부시키가이샤 | 악성 종양 치료용 제제 및 조성물 |
LT3497103T (lt) * | 2016-08-15 | 2021-07-26 | Pfizer Inc. | Piridopirimidinono cdk2/4/6 inhibitoriai |
JP7027699B2 (ja) * | 2017-05-09 | 2022-03-02 | 住友ゴム工業株式会社 | タイヤトレッドおよびタイヤ |
US11833151B2 (en) | 2018-03-19 | 2023-12-05 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition including sodium alkyl sulfate |
MX2022001863A (es) | 2019-08-12 | 2022-05-30 | Deciphera Pharmaceuticals Llc | Metodos para tratar los tumores del estroma gastrointestinal. |
WO2021030405A1 (fr) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib pour le traitement de tumeurs stromales gastro-intestinales |
JP2023505690A (ja) * | 2019-12-10 | 2023-02-10 | ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー | 複製タンパク質a(rpa)-dna相互作用阻害剤 |
RS65058B1 (sr) | 2019-12-30 | 2024-02-29 | Deciphera Pharmaceuticals Llc | Formulacije inhibitora amorfne kinaze i postupci njihove primene |
BR112022013169A2 (pt) | 2019-12-30 | 2022-09-13 | Deciphera Pharmaceuticals Llc | Composições de 1-(4-bromo-5-(1-etil-7-(metilamino)-2-oxo-1,2-diidro-1,6-naftiridin-3-il)-2-fluorofeil)-3-fenilurea |
KR102195221B1 (ko) | 2019-12-31 | 2020-12-24 | 서울대학교산학협력단 | 포스파티딜이노시톨 3-키나아제 억제제 및 프로그램화 세포 사멸 단백질 1 억제제를 포함하는, 삼중음성 유방암의 방사선 병용 치료용 약학적 조성물 |
CN111358952B (zh) * | 2020-04-15 | 2022-03-15 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | 一种抗肿瘤药物组合物及其制剂和应用 |
WO2023092104A1 (fr) * | 2021-11-18 | 2023-05-25 | Onconova Therapeutics, Inc. | Méthodes et compositions pour traitement du cancer |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7019002B2 (en) * | 2001-12-11 | 2006-03-28 | Pharmacia & Upjohn, S.P.A. | Pyridopyrimidinones derivatives as telomerase inhibitors |
EP2277867B1 (fr) * | 2002-07-15 | 2012-12-05 | Symphony Evolution, Inc. | Composés, compositions pharmaceutiques les contenants et leur utilisation pour traiter le cancer |
CA2555724A1 (fr) | 2004-02-18 | 2005-09-09 | Warner-Lambert Company Llc | 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
US20080255162A1 (en) * | 2004-05-04 | 2008-10-16 | Warner-Lambert Company Llc | Pyrrolyl Substituted Pyrido[2,3-D]Pyrimidin-7-Ones and Derivatives Thereof as Therapeutic Agents |
WO2007004698A1 (fr) * | 2005-07-06 | 2007-01-11 | Sbc Corporation | Dispositif et procédé de détection de courant de fuite |
JP5270353B2 (ja) | 2005-10-07 | 2013-08-21 | エクセリクシス, インク. | ホスファチジルイノシトール3−キナーゼインヒビターとその使用方法 |
CA2624965A1 (fr) * | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | Inhibiteurs pyridopyrimidinone de pi3ka |
BRPI0617159B8 (pt) | 2005-10-07 | 2021-05-25 | Exelixis Inc | compostos de piridopirimidinone inibidores de pi3ka, composições que os contem e processo para preparo |
AU2007284562B2 (en) | 2006-08-16 | 2013-05-02 | Exelixis, Inc. | Using PI3K and MEK modulators in treatments of cancer |
WO2008032162A1 (fr) * | 2006-09-15 | 2008-03-20 | Pfizer Products Inc. | Composés de pyrido (2, 3-d) pyrimidin0ne et leur utilisation en tant qu'inhibiteurs de pi3 |
UA100979C2 (ru) | 2007-04-10 | 2013-02-25 | Экселиксис, Инк. | Применение пиридопиримидиноновых ингибиторов pi3k альфа для лечения рака |
AU2008239596B2 (en) | 2007-04-11 | 2013-08-15 | Exelixis, Inc. | Pyrido [2,3-D] pyrimidin-7-one compounds as inhibitors of PI3K-alpha for the treatment of cancer |
WO2008127594A2 (fr) | 2007-04-11 | 2008-10-23 | Exelixis, Inc. | Procédés de traitement impliquant l'inhibition de pi3k-alpha au moyen d'inhibiteurs de type quinaxoline |
EP2142543B8 (fr) | 2007-04-11 | 2013-07-03 | Exelixis, Inc. | Composés pyrido [2, 3-d]pyrimidin-7-one utilisés en tant qu'inhibiteurs de pi3k-alpha pour le traitement du cancer |
PA8843901A1 (es) | 2008-09-30 | 2010-05-26 | INHIBIDORES DE PIRIMIDINONA DE PI3K( ALFA) Y m TOR |
-
2008
- 2008-04-09 UA UAA200911419A patent/UA100979C2/ru unknown
- 2008-04-09 CA CA2683641A patent/CA2683641C/fr not_active Expired - Fee Related
- 2008-04-09 KR KR1020097023351A patent/KR101626435B1/ko active IP Right Grant
- 2008-04-09 NZ NZ580110A patent/NZ580110A/en not_active IP Right Cessation
- 2008-04-09 CN CN201210032620.4A patent/CN102727498B/zh not_active Expired - Fee Related
- 2008-04-09 US US12/595,219 patent/US8513266B2/en active Active
- 2008-04-09 PT PT87426771T patent/PT2139484E/pt unknown
- 2008-04-09 MY MYPI20094214 patent/MY150697A/en unknown
- 2008-04-09 WO PCT/US2008/004573 patent/WO2008124161A1/fr active Application Filing
- 2008-04-09 AU AU2008236562A patent/AU2008236562B2/en not_active Ceased
- 2008-04-09 SI SI200831004T patent/SI2139484T1/sl unknown
- 2008-04-09 CN CN200880018725A patent/CN101715345A/zh active Pending
- 2008-04-09 EA EA200970932A patent/EA020022B1/ru not_active IP Right Cessation
- 2008-04-09 ME MEP-2009-303A patent/ME00936B/fr unknown
- 2008-04-09 MX MX2009010930A patent/MX2009010930A/es active IP Right Grant
- 2008-04-09 BR BRPI0810206-6A2A patent/BRPI0810206A2/pt not_active IP Right Cessation
- 2008-04-09 JP JP2010503045A patent/JP2010523670A/ja active Pending
- 2008-04-09 DK DK08742677.1T patent/DK2139484T3/da active
- 2008-04-09 ES ES08742677T patent/ES2430614T3/es active Active
- 2008-04-09 RS RS20130384A patent/RS52939B/en unknown
- 2008-04-09 EP EP08742677.1A patent/EP2139484B9/fr active Active
- 2008-04-09 PL PL08742677T patent/PL2139484T3/pl unknown
-
2009
- 2009-09-29 ZA ZA200906764A patent/ZA200906764B/xx unknown
- 2009-09-30 TN TNP2009000400A patent/TN2009000400A1/fr unknown
- 2009-10-01 IL IL201284A patent/IL201284A/en active IP Right Grant
- 2009-10-09 DO DO2009000243A patent/DOP2009000243A/es unknown
- 2009-10-09 HN HN2009003002A patent/HN2009003002A/es unknown
- 2009-11-02 MA MA32318A patent/MA31358B1/fr unknown
- 2009-11-09 CO CO09126924A patent/CO6251254A2/es not_active Application Discontinuation
- 2009-11-09 EC EC2009009724A patent/ECSP099724A/es unknown
- 2009-11-09 CR CR11100A patent/CR11100A/es unknown
-
2010
- 2010-07-05 HK HK10106503.5A patent/HK1139863A1/xx not_active IP Right Cessation
-
2013
- 2013-07-22 HR HRP20130688AT patent/HRP20130688T1/hr unknown
- 2013-09-19 JP JP2013194611A patent/JP2014034576A/ja active Pending
-
2014
- 2014-03-24 JP JP2014059561A patent/JP2014139217A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA31358B1 (fr) | Méthodes de traitement du cancer à l'aide d'inhibiteurs de pi3k alpha à base de pyridopyrimidinone | |
MA31335B1 (fr) | Procédés de traitement impliquant l'inhibition de pi3k-alpha au moyen d'inhibiteurs de type quinaxoline | |
EA201270570A1 (ru) | Комбинированная терапия раковых заболеваний с помощью соединений-ингибиторов hsp90 | |
MX2009009786A (es) | Inhibidores de la via de hedgehog. | |
CR11510A (es) | Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer | |
EA200970542A1 (ru) | ИНГИБИТОРЫ ДЕЙСТВИЯ Akt | |
ECSP099436A (es) | Acilaminopirazoles como inhibidores de fgfr | |
CA2897273C (fr) | Derives de benzylamine | |
EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
MA32135B1 (fr) | Inhibiteurs de pim kinase et leurs procedes d'utilisation | |
ECSP088902A (es) | Derivados de pirazolo[3,4-d]-pirimidina utiles para tratar trastornos respiratorios | |
TW201000473A (en) | Benzene or thiophene derivative and use thereof as VAP-1 inhibitor | |
CR20200286A (es) | DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294) | |
CR20110339A (es) | Compuestos útiles para inhibir chk1 | |
EA201490254A1 (ru) | Комбинированное лечение гепатита с | |
EA201100391A1 (ru) | Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы | |
MX2010008460A (es) | Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular. | |
EA200970936A1 (ru) | СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА | |
BRPI0916540B8 (pt) | inibidores do canal de ânion de superficíe de plasmódio como agentes antimaláricos | |
AR084216A1 (es) | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit | |
MA35347B1 (fr) | Procedes therapeuiques | |
UA96969C2 (en) | Acylaminopyrazoles as fgfr inhibitors | |
WO2010121675A3 (fr) | Thiazolyl-benzimidazoles | |
EA201270347A1 (ru) | Производные апогоссиполона в качестве противоопухолевых агентов | |
UA99612C2 (en) | Inhibitors of the hedgehog pathway |